PFG
NBIX icon

Piershale Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Piershale Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$28.3K Hold
300
– – 0.02% 61
2023
Q1 		$30.4K Hold
300
– – 0.02% 48
2022
Q4 		$35.8K Buy
+300
New +$35.1K 0.03% 44

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Piershale Financial Group's NBIX Position: Q2 2023 in Review

Piershale Financial Group held its Neurocrine Biosciences (NBIX) position steady in Q2 2023 at 300 shares worth $28.3K. The position accounts for 0.02% of the portfolio, ranked #61.

Piershale Financial Group first reported a position in NBIX in Q4 2022 and has held it in 3 quarters since. The position peaked at $35.8K in Q4 2022. 457 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Piershale Financial Group held 300 shares of Neurocrine Biosciences worth $28.3K as of Q2 2023.
  • Piershale Financial Group left its Neurocrine Biosciences share count unchanged in Q2 2023.
  • Neurocrine Biosciences made up 0.02% of Piershale Financial Group's portfolio in Q2 2023, its #61 holding.
  • Piershale Financial Group first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 3 quarters since.
  • Piershale Financial Group's Neurocrine Biosciences position peaked at $35.8K in Q4 2022.
  • 457 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Piershale Financial Group's 13F filing for Q2 2023, filed 6 Jul 2023.